Key Highlights

  • Revenue was USD 3.82 million against an estimate of USD 1.28 million.
  • Loss per share was USD 0.06 against an estimate of a USD 0.08 loss.
  • Cash, deposits and marketable securities were approximately USD 117.5 million.
  • MAIA-Ovarian enrollment is complete, with data scheduled by the end of Q1 2027.

Compugen (NASDAQ:CGEN) reported third quarter 2026 Revenue of USD 3.82 million, against an estimate of USD 1.28 million. The loss per share was USD 0.06, compared with an estimate of a USD 0.08 loss. The company's chief financial officer said revenue was approximately USD 3.8 million, compared with approximately USD 1.9 million in the same quarter of 2025.

The revenue in both periods reflects the recognition of portions of the upfront payment and the IND milestone payment under the license agreement with Gilead. Net loss for the quarter was approximately USD 5.8 million, or USD 0.06 per basic and diluted share, compared with approximately USD 7 million, or USD 0.07 per share, in the third quarter of 2025. Research and Development expenses were approximately USD 5.8 million in each of the third quarters of 2026 and 2025, and general and administrative expenses were approximately USD 2.3 million.

Cash Position

As of September 30, 2026, the company had approximately USD 117.5 million in cash, cash equivalents, short-term bank deposits and investments in marketable securities. Management said that, assuming no further cash inflows, its cash runway funds operating plans into 2029, and described expenses in the quarter as in line with plans.

Clinical Program Update

The call included the president and chief executive officer, Eran Ophir, the chief financial officer and the chief medical officer. Management described its Balance Sheet as solid at the end of the quarter and said it completed enrollment in MAIA-Ovarian, a global randomized trial evaluating COM701, a potential first-in-class anti-PVRIG antibody, as maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer. The company stated it anticipates reporting data by the end of the first quarter of 2027, and management repeated that it looks forward to sharing the results by that date.

Partnered Programs

The company said its partnered programs carry the potential for more than USD 1 billion in future milestone payments and royalties. During the quarter, AstraZeneca reported first overall survival data from the Phase II ARTEMIDE-01 study in first-line PD-L1 positive non-small cell lung cancer at the World Conference on Lung Cancer. Compugen is eligible to receive up to USD 195 million in regulatory and commercial milestones and up to mid-single-digit royalties on worldwide sales of rilvegostomig.

Under the Gilead agreement, Compugen has received gross payments totaling USD 90 million and is eligible for up to USD 758 million in additional milestone payments plus tiered royalties ranging from single digits to low double digits.

Compugen Q3 2026 Earnings: Key Takeaways

Compugen reported third quarter 2026 revenue of USD 3.82 million and a loss per share of USD 0.06. The company held approximately USD 117.5 million in cash and investments, completed enrollment in MAIA-Ovarian and described partnered programs with potential milestone payments and royalties exceeding USD 1 billion.